These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11380465)

  • 1. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.
    Béné MC; Bernier M; Casasnovas RO; Castoldi G; Doekharan D; van der Holt B; Knapp W; Lemez P; Ludwig WD; Matutes E; Orfao A; Schoch C; Sperling C; van't Veer MB
    Br J Haematol; 2001 Jun; 113(3):737-45. PubMed ID: 11380465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.
    Arber DA; Stein AS; Carter NH; Ikle D; Forman SJ; Slovak ML
    Am J Clin Pathol; 2003 May; 119(5):672-80. PubMed ID: 12760285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.
    Suzuki R; Murata M; Kami M; Ohtake S; Asou N; Kodera Y; Tomonaga M; Masaki Y; Kusumoto S; Takeuchi J; Matsuda S; Hirai H; Yorimitsu mS; Hamajima N; Seto M; Shimoyama M; Ohno R; Morishima Y; Nakamura S
    Int J Hematol; 2003 Jun; 77(5):482-9. PubMed ID: 12841387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings.
    Cuneo A; Ferrant A; Michaux JL; Boogaerts M; Demuynck H; Van Orshoven A; Criel A; Stul M; Dal Cin P; Hernandez J
    Blood; 1995 Jun; 85(12):3688-94. PubMed ID: 7780152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance.
    Meckenstock G; Aul C; Hildebrandt B; Heyll A; Germing U; Wehmeier A; Giagounidis A; Suedhoff T; Burk M; Soehngen D; Schneider W
    Leuk Lymphoma; 1998 May; 29(5-6):523-31. PubMed ID: 9643566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.
    Huang SY; Tang JL; Jou ST; Tsay W; Hu CH; Lin DT; Lin KS; Lin KS; Wang CH; Chen YC; Shen MC; Tien HF
    Leukemia; 1999 Oct; 13(10):1506-12. PubMed ID: 10516750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia.
    Ogata K; Yokose N; Shioi Y; Ishida Y; Tomiyama J; Hamaguchi H; Yagasaki F; Bessyo M; Sakamaki H; Dan K; Kuriya S
    Br J Haematol; 2001 Dec; 115(3):612-5. PubMed ID: 11736944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia].
    Braham-Jmili N; Sendi-Senana H; Labiadh S; Ben Abdelali R; Ben Abdelaziz A; Khelif A; Saad A; Kortas M
    Ann Biol Clin (Paris); 2006; 64(5):457-65. PubMed ID: 17040877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
    van der Holt B; Breems DA; Berna Beverloo H; van den Berg E; Burnett AK; Sonneveld P; Löwenberg B
    Br J Haematol; 2007 Jan; 136(1):96-105. PubMed ID: 17129222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia.
    Udayakumar AM; Pathare AV; Al-Kindi S; Khan H; Rehmen JU; Zia F; Al-Ghazaly A; Nusrut N; Khan MI; Wali YA; Al-Lamki Z; Dennison D; Raeburn JA
    Cancer Genet Cytogenet; 2007 Sep; 177(2):89-94. PubMed ID: 17854660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
    Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
    J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia.
    Li X; Li J; Du W; Zhang J; Liu W; Chen X; Li H; Huang S; Li X
    APMIS; 2011 Jan; 119(1):76-84. PubMed ID: 21143529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic findings in acute biphenotypic leukaemia.
    Carbonell F; Swansbury J; Min T; Matutes E; Farahat N; Buccheri V; Morilla R; Secker-Walker L; Catovsky D
    Leukemia; 1996 Aug; 10(8):1283-7. PubMed ID: 8709632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA; Le Beau MM
    Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
    Schwartz S; Heinecke A; Zimmermann M; Creutzig U; Schoch C; Harbott J; Fonatsch C; Löffler H; Büchner T; Ludwig WD; Thiel E
    Leuk Lymphoma; 1999 Jun; 34(1-2):85-94. PubMed ID: 10350335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study.
    Miyazaki Y; Kuriyama K; Miyawaki S; Ohtake S; Sakamaki H; Matsuo T; Emi N; Kobayashi T; Matsushima T; Shinagawa K; Ohno R; Tomonaga M;
    Br J Haematol; 2003 Jan; 120(1):56-62. PubMed ID: 12492577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.